| Nome |
# |
|
Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response, file e3ad8926-d423-da0e-e053-3705fe0a2b96
|
295
|
|
Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility, file e3ad8926-e431-da0e-e053-3705fe0a2b96
|
91
|
|
Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing, file e3ad8926-f8e1-da0e-e053-3705fe0a2b96
|
87
|
|
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia, file e3ad8926-1e53-da0e-e053-3705fe0a2b96
|
74
|
|
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients, file e3ad8926-f32d-da0e-e053-3705fe0a2b96
|
68
|
|
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens, file e3ad8927-125d-da0e-e053-3705fe0a2b96
|
68
|
|
Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev), file e3ad8926-e6cf-da0e-e053-3705fe0a2b96
|
65
|
|
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients, file e3ad8926-fbd0-da0e-e053-3705fe0a2b96
|
64
|
|
Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report, file e3ad8926-be9f-da0e-e053-3705fe0a2b96
|
62
|
|
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: Do we still need it?, file e3ad8926-c46c-da0e-e053-3705fe0a2b96
|
62
|
|
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies, file e3ad8927-4c34-da0e-e053-3705fe0a2b96
|
62
|
|
Mouse models of multiple myeloma: Technologic platforms and perspectives, file e3ad8926-c61e-da0e-e053-3705fe0a2b96
|
57
|
|
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients, file e3ad8926-df77-da0e-e053-3705fe0a2b96
|
56
|
|
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients, file e3ad8926-b345-da0e-e053-3705fe0a2b96
|
55
|
|
Mechanisms of immune evasion in multiple myeloma: Open questions and therapeutic opportunities, file e3ad8926-df23-da0e-e053-3705fe0a2b96
|
55
|
|
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival, file e3ad8926-fa13-da0e-e053-3705fe0a2b96
|
55
|
|
Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report, file e3ad8926-acfd-da0e-e053-3705fe0a2b96
|
54
|
|
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths, file e3ad8927-0530-da0e-e053-3705fe0a2b96
|
54
|
|
Myeloid derived suppressor cells in multiple myeloma: Preclinical research and translational opportunities, file e3ad8926-d803-da0e-e053-3705fe0a2b96
|
53
|
|
Replacement of miR-155 elicits tumor suppressive activity and antagonizes bortezomib resistance in multiple myeloma, file e3ad8927-03a9-da0e-e053-3705fe0a2b96
|
53
|
|
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again, file 699667e5-1bab-4bbc-91a4-0ac75e8d7042
|
52
|
|
OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes, file e3ad8926-e6d1-da0e-e053-3705fe0a2b96
|
52
|
|
Tumor infiltration by chemokine receptor 7 (CCR7)+ T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer, file e3ad8926-f1e4-da0e-e053-3705fe0a2b96
|
52
|
|
Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human primates, file e3ad8926-d3af-da0e-e053-3705fe0a2b96
|
51
|
|
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up, file e3ad8926-e0bf-da0e-e053-3705fe0a2b96
|
51
|
|
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm, file e3ad8926-c129-da0e-e053-3705fe0a2b96
|
50
|
|
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma, file e3ad8926-c61d-da0e-e053-3705fe0a2b96
|
50
|
|
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice, file e3ad8926-d2d9-da0e-e053-3705fe0a2b96
|
46
|
|
The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response, file e3ad8927-0826-da0e-e053-3705fe0a2b96
|
45
|
|
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach, file fe476190-2ed0-49a6-bb02-113d33d680d5
|
38
|
|
Network meta-analysis of randomized trials in multiple myeloma efficacy and safety in frontline therapy for patients not eligible for transplant, file 5d6af52c-b54e-4580-9b3c-db809c51e5f3
|
34
|
|
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection, file e3ad8928-9711-da0e-e053-3705fe0a2b96
|
29
|
|
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients, file e3ad8926-fa14-da0e-e053-3705fe0a2b96
|
27
|
|
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma, file 42d9ef0f-1273-4690-8651-d872b6daadfd
|
23
|
|
Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma, file 0b7f169b-efaa-4d1c-89dc-31aeab6caa9c
|
22
|
|
B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma, file 5fb8411d-d86a-495e-888c-20db9df682b1
|
22
|
|
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome, file 4bc99ea1-79a6-4a62-bef3-7def52c2f62d
|
21
|
|
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials, file 813882ef-0d65-443d-a2cb-4a5dbcbbcd64
|
14
|
|
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials, file 0e0fd674-ef32-4778-9ffb-6d59e751b989
|
12
|
|
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma, file e3ad8927-852d-da0e-e053-3705fe0a2b96
|
9
|
|
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance, file a9a27aa5-259f-46e4-b742-183310b4c5a1
|
8
|
|
Multiple Myeloma in 2023 Ways: From Trials to Real Life, file 0004f926-f7cf-4a6e-9947-21129aa2e836
|
7
|
|
Immunologic characterization of COVID-19 patients with hematological cancer, file e3ad8926-fd9f-da0e-e053-3705fe0a2b96
|
7
|
|
Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy, file e3ad8927-74fd-da0e-e053-3705fe0a2b96
|
7
|
|
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials, file e3ad8926-be9a-da0e-e053-3705fe0a2b96
|
6
|
|
Unveiling Novel Therapeutic Targets for CAR Therapy in Multiple Myeloma through Single-Cell RNA Sequencing, file d44e8885-402a-4062-892d-84c4844e7440
|
5
|
|
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study, file e3ad8926-eb9a-da0e-e053-3705fe0a2b96
|
5
|
|
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma, file 37b0d1bd-06c3-43bd-a44e-7e11d7673128
|
4
|
|
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology, file 4f0ad65c-7364-4ca4-a652-b347b023fa1b
|
4
|
|
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab, file e3ad8926-c12b-da0e-e053-3705fe0a2b96
|
4
|
|
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?, file e3ad8926-d2da-da0e-e053-3705fe0a2b96
|
4
|
|
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab, file e3ad8926-e36d-da0e-e053-3705fe0a2b96
|
4
|
|
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials, file e3ad8928-d090-da0e-e053-3705fe0a2b96
|
4
|
|
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials, file e3ad8928-e802-da0e-e053-3705fe0a2b96
|
4
|
|
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma, file 6708afce-5b3b-48a7-a676-5416fb081861
|
3
|
|
Could PD-1/PDL1 immune checkpoints be linked to HLA signature?, file c6d30281-0f7f-4092-8efb-dc57d8f6e358
|
3
|
|
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study, file e3ad8926-ba01-da0e-e053-3705fe0a2b96
|
3
|
|
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?, file e3ad8926-c61b-da0e-e053-3705fe0a2b96
|
3
|
|
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation, file e3ad8927-092d-da0e-e053-3705fe0a2b96
|
3
|
|
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma, file e3ad8927-122d-da0e-e053-3705fe0a2b96
|
3
|
|
Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma, file 5f06d20d-4343-4078-a8c3-301833ed7012
|
2
|
|
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma, file ab846d3f-83fa-4492-b584-316581ec03a4
|
2
|
|
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination, file e3ad8926-e6cd-da0e-e053-3705fe0a2b96
|
2
|
|
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies, file e3ad8926-fa10-da0e-e053-3705fe0a2b96
|
2
|
|
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma, file e3ad8927-06db-da0e-e053-3705fe0a2b96
|
2
|
|
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma, file e3ad8927-0f10-da0e-e053-3705fe0a2b96
|
2
|
|
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients, file e3ad8927-125f-da0e-e053-3705fe0a2b96
|
2
|
|
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology, file e3ad8927-3e34-da0e-e053-3705fe0a2b96
|
2
|
|
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients, file e3ad8927-4dd2-da0e-e053-3705fe0a2b96
|
2
|
|
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report, file e3ad8927-88fa-da0e-e053-3705fe0a2b96
|
2
|
|
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation, file 5f00ffaa-e823-4607-ac7c-97aeee5c78aa
|
1
|
|
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution, file db63ba75-f2e9-44b3-8bba-b4a54a39eb75
|
1
|
|
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse, file e3ad8926-a890-da0e-e053-3705fe0a2b96
|
1
|
|
Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients, file e3ad8926-a98a-da0e-e053-3705fe0a2b96
|
1
|
|
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials, file e3ad8926-b24c-da0e-e053-3705fe0a2b96
|
1
|
|
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma, file e3ad8926-bae1-da0e-e053-3705fe0a2b96
|
1
|
|
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells, file e3ad8926-bdc8-da0e-e053-3705fe0a2b96
|
1
|
|
Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation, file e3ad8926-be9e-da0e-e053-3705fe0a2b96
|
1
|
|
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro, file e3ad8926-bea7-da0e-e053-3705fe0a2b96
|
1
|
|
The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells, file e3ad8926-c12c-da0e-e053-3705fe0a2b96
|
1
|
|
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial, file e3ad8926-c46a-da0e-e053-3705fe0a2b96
|
1
|
|
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in relapsed/refractory patients, file e3ad8926-c61a-da0e-e053-3705fe0a2b96
|
1
|
|
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients, file e3ad8926-c61c-da0e-e053-3705fe0a2b96
|
1
|
|
Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer, file e3ad8926-c84a-da0e-e053-3705fe0a2b96
|
1
|
|
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis, file e3ad8926-d5db-da0e-e053-3705fe0a2b96
|
1
|
|
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo, file e3ad8926-d9a9-da0e-e053-3705fe0a2b96
|
1
|
|
Immunomodulatory activity of microRNAs: Potential implications for multiple myeloma treatment, file e3ad8926-db50-da0e-e053-3705fe0a2b96
|
1
|
|
A p53-Dependent Tumor Suppressor Network Is Induced by Selective miR-125a-5p Inhibition in Multiple Myeloma Cells, file e3ad8926-e05f-da0e-e053-3705fe0a2b96
|
1
|
|
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients, file e3ad8926-e204-da0e-e053-3705fe0a2b96
|
1
|
|
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine, file e3ad8926-e6d2-da0e-e053-3705fe0a2b96
|
1
|
|
Immunotherapy of colorectal cancer: New perspectives after a long path, file e3ad8926-ec01-da0e-e053-3705fe0a2b96
|
1
|
|
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis, file e3ad8926-f5d5-da0e-e053-3705fe0a2b96
|
1
|
|
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials, file e3ad8926-fa0f-da0e-e053-3705fe0a2b96
|
1
|
|
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease, file e3ad8927-06d6-da0e-e053-3705fe0a2b96
|
1
|
|
Immunologic microenvironment and personalized treatment in multiple myeloma, file e3ad8927-06dc-da0e-e053-3705fe0a2b96
|
1
|
|
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts, file e3ad8927-07d5-da0e-e053-3705fe0a2b96
|
1
|
|
A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma, file e3ad8927-9418-da0e-e053-3705fe0a2b96
|
1
|
|
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials, file e3ad8928-cd74-da0e-e053-3705fe0a2b96
|
1
|
| Totale |
2.329 |